Numerous staging and scoring systems exist for differentiated thyroid cancer (DTC), but all harbor limitations. This has prompted investigation for new factors with prognostic implications for DTC.
Several new factors that may be involved in DTC risk stratification have emerged, such as thyroid stimulating hormone and molecular markers. In addition, others are controversial and being challenged, such as age, sex and lymph node involvement.
The purpose of this review is to present recent updates in the literature on new potential risk stratification predictors for DTC.
aDivision of Metabolism, Endocrinology and Diabetes
bDivision of Metabolism, Endocrinology and Diabetes, and Hematology/Oncology, Department of Medicine, Ann Arbor, Michigan, USA
Correspondence to Megan R. Haymart, MD, Assistant Professor of Medicine, Division of Metabolism, Endocrinology and Diabetes, and Hematology/Oncology, Department of Medicine, North Campus Research Complex, Building 16 Rm. 408E, University of Michigan Health System, Ann Arbor, MI 48109, USA. Tel: +1 (734) 615 6745; fax: +1 (734) 936 8944; e-mail: firstname.lastname@example.org